Australia markets open in 1 hour 17 minutes

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.13+3.50 (+214.72%)
At close: 04:00PM EDT
4.74 -0.39 (-7.60%)
After hours: 06:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 110.74M
Enterprise value -49.79M
Trailing P/E N/A
Forward P/E 40.82
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.19
Price/book (mrq)5.04
Enterprise value/revenue -0.49
Enterprise value/EBITDA 11.56

Trading information

Stock price history

Beta (5Y monthly) 1.02
52-week change 3-1.21%
S&P500 52-week change 323.10%
52-week high 35.85
52-week low 31.04
50-day moving average 32.05
200-day moving average 31.60

Share statistics

Avg vol (3-month) 3946.26k
Avg vol (10-day) 3350.57k
Shares outstanding 567.73M
Implied shares outstanding 667.73M
Float 853.83M
% held by insiders 11.19%
% held by institutions 148.51%
Shares short (15 Apr 2024) 43.59M
Short ratio (15 Apr 2024) 44.89
Short % of float (15 Apr 2024) 45.35%
Short % of shares outstanding (15 Apr 2024) 45.31%
Shares short (prior month 15 Mar 2024) 43.53M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -0.56%
Operating margin (ttm)-2.28%

Management effectiveness

Return on assets (ttm)-1.75%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)101.21M
Revenue per share (ttm)1.37
Quarterly revenue growth (yoy)32.20%
Gross profit (ttm)N/A
EBITDA -4.31M
Net income avi to common (ttm)-569k
Diluted EPS (ttm)-0.01
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)174.51M
Total cash per share (mrq)2.58
Total debt (mrq)13.97M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.17
Book value per share (mrq)-0.70

Cash flow statement

Operating cash flow (ttm)-56.03M
Levered free cash flow (ttm)43.66M